230 related articles for article (PubMed ID: 22019475)
21. One-step immunostrip test for the simultaneous detection of free and total prostate specific antigen in serum.
Fernández-Sánchez C; McNeil CJ; Rawson K; Nilsson O; Leung HY; Gnanapragasam V
J Immunol Methods; 2005 Dec; 307(1-2):1-12. PubMed ID: 16277989
[TBL] [Abstract][Full Text] [Related]
22. Development of novel peptide ligands modulating the enzyme activity of prostate-specific antigen.
Leinonen J; Wu P; Koivunen E; Närvänen A; Stenman UH
Scand J Clin Lab Invest Suppl; 2000; 233():59-64. PubMed ID: 11317943
[TBL] [Abstract][Full Text] [Related]
23. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR
J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285
[TBL] [Abstract][Full Text] [Related]
24. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
Tsuchiya N; Ohyama C; Habuchi T
Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
[TBL] [Abstract][Full Text] [Related]
25. Cloning and characterization of a single-chain fragment of monoclonal antibody to ACE suitable for lung endothelial targeting.
Balyasnikova IV; Berestetskaya JV; Visintine DJ; Nesterovitch AB; Adamian L; Danilov SM
Microvasc Res; 2010 Dec; 80(3):355-64. PubMed ID: 20888351
[TBL] [Abstract][Full Text] [Related]
26. Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain.
Almagro JC; Raghunathan G; Beil E; Janecki DJ; Chen Q; Dinh T; LaCombe A; Connor J; Ware M; Kim PH; Swanson RV; Fransson J
J Mol Recognit; 2012 Mar; 25(3):125-35. PubMed ID: 22407976
[TBL] [Abstract][Full Text] [Related]
27. Three immunoassays based on monoclonal antibodies specific for prostate specific antigen (PSA), alpha-1-antichymotrypsin (ACT), and the PSA-ACT complex.
Wan XS; Xu YA; Ware JH; Kennedy AR
Prostate; 2003 Jul; 56(2):131-41. PubMed ID: 12746838
[TBL] [Abstract][Full Text] [Related]
28. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH.
Abrahamsson PA; Kuriyama M
Hinyokika Kiyo; 1998 Apr; 44(4):223-32. PubMed ID: 9617617
[TBL] [Abstract][Full Text] [Related]
29. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.
Stenman UH; Leinonen J; Alfthan H; Rannikko S; Tuhkanen K; Alfthan O
Cancer Res; 1991 Jan; 51(1):222-6. PubMed ID: 1703033
[TBL] [Abstract][Full Text] [Related]
30. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
[TBL] [Abstract][Full Text] [Related]
31. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer.
Van Cangh PJ; De Nayer P; Sauvage P; Tombal B; Elsen M; Lorge F; Opsomer R; Wese FX
Prostate Suppl; 1996; 7():30-4. PubMed ID: 8950361
[TBL] [Abstract][Full Text] [Related]
32. alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer.
Fukushima K; Satoh T; Baba S; Yamashita K
Glycobiology; 2010 Jan; 20(4):452-60. PubMed ID: 20008118
[TBL] [Abstract][Full Text] [Related]
33. Overcoming antibody expression and screening limitations by smart design: applications to PSA immunoassay development.
Hayes CJ; Leonard P; O'Kennedy R
Protein Expr Purif; 2012 May; 83(1):84-91. PubMed ID: 22433448
[TBL] [Abstract][Full Text] [Related]
34. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains.
van den Beucken T; van Neer N; Sablon E; Desmet J; Celis L; Hoogenboom HR; Hufton SE
J Mol Biol; 2001 Jul; 310(3):591-601. PubMed ID: 11439026
[TBL] [Abstract][Full Text] [Related]
35. Production of an anti-prostate-specific antigen single-chain antibody fragment from Pichia pastoris.
Wang Y; Wang K; Jette DC; Wishart DS
Protein Expr Purif; 2001 Dec; 23(3):419-25. PubMed ID: 11722178
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Luque P; Corral JM; Augé JM; Coca F
Anticancer Res; 2007; 27(1B):607-10. PubMed ID: 17348449
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.
Wang X; Campoli M; Ko E; Luo W; Ferrone S
J Immunol Methods; 2004 Nov; 294(1-2):23-35. PubMed ID: 15604013
[TBL] [Abstract][Full Text] [Related]
38. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
Romppanen J; Haapalainen T; Punnonen K; Penttilä I
Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325
[TBL] [Abstract][Full Text] [Related]
39. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
40. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients.
Beneduce L; Prayer-Galetti T; Giustinian AM; Gallotta A; Betto G; Pagano F; Fassina G
Cancer Detect Prev; 2007; 31(5):402-7. PubMed ID: 18035503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]